Nutrition 21
This article was originally published in The Tan Sheet
Executive Summary
Private placement to institutional and private investors including SF Capital Partners and P.A.W. Long Term Partners raises $3.25 mil., which firm plans to use for "continued clinical and market development of Diachrome," Nutrition 21 reports Oct. 14. Purchase, N.Y.-based company expects 600-person clinical study for the chromium and biotin combination product to be complete by June 30, 2004. Nutriton 21 will conduct a limited roll out of Diachrome until completion of the research (1"The Tan Sheet" Jan. 6, 2003, p. 13)...
You may also be interested in...
Nutrition 21 Diachrome, Zeramax Sales To Be Backed By Research Initiatives
Nutrition 21 plans to support the broad launch of its Diachrome chromium picolinate/biotin blend with a relatively large-scale clinical study, according to President and CEO Gail Montgomery
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.